Cyclophilin inhibitors for hepatitis C therapy.
Clin Liver Dis
; 17(1): 129-39, 2013 Feb.
Article
em En
| MEDLINE
| ID: mdl-23177289
ABSTRACT
This article highlights a unique time in the history of hepatitis C therapy. In the last few years new families of direct-acting antivirals have emerged, that block different viral proteins to interrupt viral replication, such as protease, NS5A inhibitors, and NS5B inhibitors. There are few host-targeted agents in development; currently cyclophilin inhibitors are the only host-targeted agents in advanced development. One of these new agents has now progressed to phase 3 clinical trials; in this review article their potential role as a future therapy to cure hepatitis C is discussed.
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Hepatite C
/
Hepacivirus
/
Ciclofilinas
/
Inibidores Enzimáticos
Limite:
Humans
Idioma:
En
Revista:
Clin Liver Dis
Assunto da revista:
GASTROENTEROLOGIA
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Estados Unidos